FDA approves Gemtesa for overactive bladder in men with benign prostatic hyperplasia
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
HealthDay on MSN4 天
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
Imbrium Therapeutics Announces Results of a Sunobinop Phase 1b Study in Patients With ...
Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...
McKnight's Senior Living5 天
FDA approves Gemtesa for overactive bladder in men with BPH
(HealthDay News) — Gemtesa (vibegron) has been approved by the US Food and Drug Administration for men with overactive bladder (OAB ... has been approved for men with OAB symptoms, including urinary ...
Too Old to Operate4 天
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
2, 2025 (HealthDay News) — Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB ... been approved for men with OAB symptoms, including ...
Renal & Urology News8 天
Gemtesa Approved for Men With OAB Symptoms Receiving BPH Treatment
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
Medscape8 天
Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder
The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...